His primary areas of study are Lung cancer, Nuclear physics, Particle physics, Large Hadron Collider and Pathology. His biological study spans a wide range of topics, including Immunohistochemistry, Radiology and Epidermal growth factor receptor. His work in Nuclear physics covers topics such as Dark matter which are related to areas like Physics beyond the Standard Model and Pion.
In Particle physics, Fred R. Hirsch works on issues like Lepton, which are connected to Boson. He has researched Large Hadron Collider in several fields, including Standard Model, Quantum chromodynamics and Invariant mass. His study in the field of Higgs sector and Two-Higgs-doublet model also crosses realms of Standard deviation.
Fred R. Hirsch mainly investigates Particle physics, Nuclear physics, Lung cancer, Atlas detector and Internal medicine. His Particle physics study which covers Lepton that intersects with Minimal Supersymmetric Standard Model. His Lung cancer research incorporates themes from Immunohistochemistry, Cancer, Epidermal growth factor receptor and Cancer research.
His research integrates issues of Gastroenterology, Surgery and Oncology in his study of Internal medicine. His studies deal with areas such as Pair production, Hadron, Quark and Branching fraction as well as Large Hadron Collider. His Pathology study integrates concerns from other disciplines, such as Lung and Adenocarcinoma.
His primary scientific interests are in Particle physics, Nuclear physics, Large Hadron Collider, Lung cancer and Atlas detector. Particle physics is closely attributed to Lepton in his study. Fred R. Hirsch interconnects Boson and Higgs boson in the investigation of issues within Nuclear physics.
His research in Large Hadron Collider tackles topics such as Muon which are related to areas like Quantum chromodynamics and Electron. His Lung cancer research includes themes of Cancer and Clinical trial. His Oncology research is multidisciplinary, incorporating perspectives in Stage, Cohort and Immunotherapy.
The scientist’s investigation covers issues in Nuclear physics, Particle physics, Large Hadron Collider, Pair production and Boson. Atlas detector, Top quark, Proton, Physics beyond the Standard Model and Invariant mass are among the areas of Nuclear physics where Fred R. Hirsch concentrates his study. His research in Standard Model, Supersymmetry, Higgs boson, Minimal Supersymmetric Standard Model and Neutralino are components of Particle physics.
His Minimal Supersymmetric Standard Model study combines topics from a wide range of disciplines, such as Electroweak interaction and Gaugino. His Large Hadron Collider research integrates issues from Quantum chromodynamics, Muon and Lepton. Fred R. Hirsch combines subjects such as Photon, Dark matter and Large extra dimension with his study of Pair production.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D Travis;Elisabeth Brambilla;Masayuki Noguchi;Andrew G Nicholson.
Journal of Thoracic Oncology (2011)
The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification
William D. Travis;Elisabeth Brambilla;Andrew G. Nicholson;Yasushi Yatabe.
Journal of Thoracic Oncology (2015)
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
Federico Cappuzzo;Fred R. Hirsch;Elisa Rossi;Stefania Bartolini.
Journal of the National Cancer Institute (2005)
Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.
Fred R. Hirsch;Marileila Varella-Garcia;Paul A. Bunn;Michael V. Di Maria.
Journal of Clinical Oncology (2003)
Lung cancer: current therapies and new targeted treatments
Fred R Hirsch;Giorgio V Scagliotti;James L Mulshine;Regina Kwon.
The Lancet (2017)
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
Fred R. Hirsch;Marileila Varella-Garcia;Paul A. Bunn;Wilbur A. Franklin.
Journal of Clinical Oncology (2006)
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch;Abigail McElhinny;Dave Stanforth;James Ranger-Moore.
Journal of Thoracic Oncology (2017)
Early Detection of Lung Cancer: Clinical Perspectives of Recent Advances in Biology and Radiology
Fred R. Hirsch;Wilbur A. Franklin;Adi F. Gazdar;Paul A. Bunn.
Clinical Cancer Research (2001)
Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.
Christine H. Chung;Kim Ely;Loris McGavran;Marileila Varella-Garcia.
Journal of Clinical Oncology (2006)
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.
Samir E. Witta;Robert M. Gemmill;Fred R. Hirsch;Christopher D. Coldren.
Cancer Research (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Colorado Boulder
University of California, Davis
University of Colorado Boulder
Tongji University
University of Colorado Denver
Aberdeen Royal Infirmary
Yale University
Emory University
Princess Margaret Cancer Centre
Nagoya University
RWTH Aachen University
University of Essex
Maja Systems
University of Padua
University of Manitoba
Skolkovo Institute of Science and Technology
Kyoto University
University of St Andrews
Brazilian Agricultural Research Corporation
Spanish National Research Council
Plant & Food Research
University of Central Florida
University of South Florida
King's College London
The University of Texas at Austin
Diego Portales University